Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis

Table 2 Multivariate regression analysis for prognostic factors

Variable	HR	95% CI	P value^a
Disease-free survival
N category (N2–3 vs. N0–1)	2.512	1.388–4.548	0.002
Overall stage (IV vs. III)	1.757	1.051–2.939	0.032
Treatment group (Control vs. investigational)	1.497	1.016–2.206	0.026
Overall survival
Overall stage (IV vs. III)	4.995	1.907–13.083	0.001
Treatment group (Control vs. investigational)	0.994	0.466–2.122	0.988
Distant metastasis-free survival
N category (N2–3 vs. N0–1)	2.791	1.344–5.793	0.006
Treatment group (Control vs. investigational)	1.409	0.779–2.549	0.251
Locoregional relapse-free survival
IC regimen (TPF vs. PF)	0.204	0.059–0.707	0.012
IC regimen (TPF vs. TP)	0.823	0.398–1.701	0.598
Treatment group (Control vs. investigational)	1.805	0.883–3.686	0.105

HR hazard ratio, CI confidence interval, IC induction chemotherapy, TPF docetaxel plus cisplatin with fluorouracil, PF cisplatin with fluorouracil, TP docetaxel with cisplatin, LDH lactate dehydrogenase
^aMultivariate P-values were calculated by Cox proportional hazard regression model with backward elimination for the following prognostic factors: gender (female vs. male), age (> 42y vs. ≤ 42y), smoking (yes vs. no), drinking (yes vs. no), family history of cancer (yes vs. no), LDH (> 245 vs. ≤ 245 U/L), IC regimen (TPF vs. PF, TPF vs. TP), concurrent chemotherapy (yes vs. no), T category (T3–4 vs. T1–2), N category (N2–3 vs. N0–1), Overall stage (IV vs. III) and treatment group (control vs. investigational)

ISSN: 1471-2407